Panobinostat and Multiple Myeloma in 2018-Reference-Cited by-同舟云学术

Panobinostat and Multiple Myeloma in 2018

Published:2018-02-14 Issue:5 Volume:23 Page:516-517
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Yee Andrew J.¹²,Raje Noopur S.¹²

Affiliation:

1. Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

2. Harvard Medical School, Boston, Massachusetts, USA

Abstract

FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2017-0644

Reference23 articles.

1. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer;Minucci;Nat Rev Cancer,2006

2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors;Pei;Clin Cancer Res,2004

3. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma;Richardson;Leuk Res,2013

4. Proteasome inhibitors in multiple myeloma: 10 years later;Moreau;Blood,2012

5. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study;Dimopoulos;Lancet Oncol,2013

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia;Journal of Personalized Medicine;2024-08-06

2. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma;Blood Advances;2024-04-29

3. Anti-Tumor Activity of Indole: A Review;Letters in Drug Design & Discovery;2024-03-08

4. Investigation of Potential Effects of Some Indole Compounds on the Glutathione S-Transferase Enzyme;Biochemistry (Moscow);2024-03

5. Amphiphilic Poly(2-oxazoline)s with Glycine-Containing Hydrophobic Blocks Tailored for Panobinostat- and Imatinib-Loaded Micelles;Biomacromolecules;2023-11-21